Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXVX0317 (Vimkunya) in Older Adults for Chikungunya
NCT05349617Phase 3Completed
- Sponsor
- Bavarian Nordic
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CHIKV VLP vaccine in chikungunya virus infection, sponsored by Bavarian Nordic. Started May 2022; status: completed.
02
Drugs
CHIKV VLP vaccine
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT05349617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349617.